The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication).  Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.

The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication).  Then,

Gilteritinib

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients we cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.